GSK (GSK) reported that its cancer drug Jemperli met its primary objective in the phase 2 AZUR-1 clinical trial.
In an exploratory analysis, 76% of 144 evaluable patients with stage II and III microsatellite instability-high mismatch repair deficient locally advanced rectal cancer achieved a complete response to Jemperli alone.
The trial also showed no disease recurrences among responders after a median follow-up of more than two years.
Jemperli recently received US approval for this indication, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments